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Background/Objectives: In vitro studies have shown that long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) can affect
inflammation; however, results from intervention studies in overweight or obese individuals are contradicting. The aim of this
study was to investigate the effects of weight loss and seafood consumption on inflammation parameters during energy
restriction.
Subjects/Methods: In this 8-week intervention trial, 324 subjects (aged 20–40 years, body mass index 27.5–32.5 kg/m2 from
Iceland, Spain and Ireland) were randomized to one of four energy-restricted diets (30% relative to estimated requirements):
salmon (3 150g/week, 2.1 g LC n-3 PUFA per day); cod (3150g/week, 0.3 g LC n-3 PUFA per day); fish oil capsules
(1.3 g LC n-3 PUFA per day); and control (sunflower oil capsules, no seafood). Body weight, high-sensitivity C-reactive protein
(CRP), interleukin-6 (IL-6), glutathione reductase and prostaglandin F2 alpha (PGEF2a) were measured at baseline and end point.
Results: Subjects experienced weight loss (5.2±3.2 kg, Po0.001). Taken together for all subjects, there were significant
decreases in all inflammation parameters. On a group level, salmon consumption was most effective, three of the four
inflammation parameters decreased in the salmon group (high-sensitivity CRP¼32.0%; IL-6¼18.4%; PGEF2a¼18.5%; all
Po0.05). Cod consumption decreased high-sensitivity CRP and IL-6 (21.5 and 10.8%, respectively, both Po0.05). Changes
in the other two groups were not significant, which can be partly explained by the large s.d.
Conclusions: The mean concentrations of inflammation parameters decreased during a period of weight loss and dietary
intervention. In our study, salmon consumption was most effective, three of the four measured inflammation parameters
decreased significantly in the salmon group.
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Introduction
Obesity-related disorders have been characterized as a
state of low-grade systemic inflammation (Forsythe
et al., 2008).Weight loss is capable of reversing the un-
favorable inflammatory profile evident in the obese state
(Forsythe et al., 2008). However, weight loss can be difficult
to maintain, and therefore additional nutritional strategies
are required (Wing and Phelan, 2005).
Studies in cell cultures and animals have shown that
supplementation with long-chain n-3 polyunsaturated fatty
acids (LC n-3 PUFAs) can decrease the production of
inflammatory markers (Arntzen et al., 1998; Bhattacharya
et al., 2007; Strandberg et al., 2009). In addition, epidemio-
logical research has indicated that intake of LC n-3 PUFAs is
inversely associated with plasma levels of inflammatory
markers (Pischon et al., 2003).
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Several intervention studies have investigated whether LC
n-3 PUFA can affect systemic inflammation (Blok et al., 1997;
Jellema et al., 2004; Sundrarjun et al., 2004; Fujioka et al.,
2006; Plat et al., 2007; Calder, 2008; Damsgaard et al., 2008).
Whereas studies in patients with immune disease such as
rheumatoid arthritis have shown potential of LC n-3 PUFA to
reduce inflammation parameters in blood and to improve
clinical outcomes (Sundrarjun et al., 2004; Calder, 2008),
evidence in overweight or obese, but otherwise healthy
subjects is not conclusive (Blok et al., 1997; Jellema et al.,
2004; Fujioka et al., 2006; Plat et al., 2007; Damsgaard et al.,
2008). Differences in inflammation parameters measured,
dosing regimes, background diets, accompanying weight loss
and sample sizes might explain some of the disagreements
observed between the studies, as well as cytokine gene
polymorphisms (Markovic et al., 2004).
It is noticeable that most intervention studies exclusively
investigated men and relatively few included women as well
(Blok et al., 1997; Jellema et al., 2004; Plat et al., 2007;
Damsgaard et al., 2008). A recent study from Japan including
healthy, mostly middle-aged subjects (59 men and
82 women) did not find changes in inflammatory markers
after daily 0.60 g eicosapentaenoic acid (EPA) and 0.26 g
docosahexaenoic acid (DHA) supplementation for 12 weeks
(Fujioka et al., 2006). The KANWU study involving Kuopio
(Finland), Aarhus (Denmark), Naples (Italy), Wollongong
(Australia) and Uppsala (Sweden), a multicenter study in
which 162 men and women were supplemented with
a much higher dose of 3.6 g n-3 PUFA per day or placebo for
3 months, also found no significant effects on plasma
PGEF2a concentration (Na¨lse´n et al., 2006).
To investigate the associations between seafood intake and
inflammatory parameters in young, overweight and obese men
and women from three European countries, the current analysis
was conducted. This article is a secondary analysis of the data
obtained from participants of the SEAFOODplus YOUNG
intervention study (Thorsdottir et al., 2007), which measured
the effects of seafood consumption on weight loss. The
hypothesis of this analysis was that the consumption of fatty
seafood, such as, salmon and fish liver oil, decreases inflamma-
tion parameters additionally to weight loss, which participants
experienced in a course of an 8-week energy-reduced diet.
Subjects and methods
Participants
A total of 324 overweight individuals (138 men and 186
women) were included in the SEAFOODplus YOUNG study
(http://www.seafoodplus.org) through advertisements, 140
from Iceland, 120 from Spain and 64 from Ireland. All
subjects were screened for inclusion and exclusion criteria.
The inclusion criteria were body mass index ranging from
27.5 to 32.5 kg/m2, age 20–40 years and waist circumference
X94 and X80 cm for men and women, respectively.
Exclusion criteria were weight change (±3 kg) due to a
weight-loss diet within 3 months before the start of the
study, use of supplements containing n-3 fatty acids, calcium
or vitamin D during the last 3 months, allergy to fish, drug
treatment of diabetes mellitus, hypertension or hyperlipide-
mia and pregnancy or lactation. Of the subjects, 85.8%
(n¼278) completed the intervention. The study was
approved by the National Bioethical Committee in Iceland
(04–031), the Ethical Committee of the University of Navarra
in Spain (24/2004) and the Clinical Research Ethics
Committee of the Cork University Hospital in Ireland. The
study followed the Helsinki guidelines, and all participating
subjects gave their written consent.
Study design
This study was a randomized, controlled dietary intervention
trial, which was conducted at the Landspitali University
Hospital in Reykjavik, Iceland, the University College of
Cork, Ireland and at the University of Navarra in Pamplona,
Spain, between April 2004 and November 2005. The
intervention lasted for 8 consecutive weeks, during which
the subjects were instructed to follow an energy-restricted
diet, 30% of the estimated energy expenditure given by
Harris–Benedict equations (Cankayali et al., 2004; Salvino
et al., 2004) and physical activity level (Nordic Council of
Ministers, 2004) (B600 (range, 473718) kcal/day). All
participants were randomly assigned to one of the following
four groups, which varied by dietary protein source and
amount of LC n-3 PUFAs:
Control, no seafood (6 sunflower oil capsules per day);
Lean fish (150 g cod, 3 times per week);
Fish oil (6 capsules per day); or
Fatty fish (150 g salmon, 3 times per week).
Groups receiving sunflower or fish oil capsules were single
blinded. All diets were designed to supply identical macro-
nutrient composition: total fat (B30% of total energy),
carbohydrate (B50% of total energy), protein (B20% of
total energy) and dietary fiber (approximately 20–25 g). Cod
diet provided LC n-3 PUFA, which resulted in a daily
consumption of B0.3 g/day; salmon diet yielded B2.1 g LC
n-3 PUFA per day; and fish oil capsules provided B1.3 g LC
n-3 PUFA per day. Other sources of n-3 fatty acids were
congruent between diet groups. The salmon diet and fish oil
supplement were originally formulated to provide a similar
amount of n-3 fatty acids. However, farmed salmon used in
this study contained twice the fat expected (US Food
Composition Database, 2005), leading to a different n-3
content in the salmon diet and in the fish oil supplement.
Each subject received a detailed meal plan to follow, as
well as recipe booklets and instructions to minimize the
difference between diets in sources of fat (other than LC n-3
PUFA), fruit and vegetable consumption and meal frequency.
The participants’ physical activity level remained unchanged
during the intervention. A validated food frequency ques-
tionnaire (Birgisdottir et al., 2008; Thorsdottir et al., 2008)
evaluated the consumption of fish and fish oil over the
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previous 4 weeks and was completed by the participants at
end point. It was asked whether the participants consumed
the fish and capsules provided to them and did not consume
any additional fish or fish oil capsules during the study
period. Consumption of fish and capsules was in good
agreement with the study protocol (Birgisdottir et al., 2008;
Thorsdottir et al., 2008).
Anthropometric measurements
All anthropometric measurements (such as waist circumfer-
ence, body weight, body height) were carried out at baseline
and at the end point of the study using standard procedures
as outlined in a research protocol approved and used by all
countries participating in the study. Body weight was
measured with the participants dressed in light underwear
on a calibrated scale (Seca 708, Seca, Hamburg, Germany).
The subjects’ height was measured using a calibrated
stadiometer (model no. 206; Seca). For the measurement of
waist circumference, the subject stood erect with the abdo-
men relaxed, arms at the sides, feet together and with their
weight equally divided over both legs. The lowest rib margin
was first located. The iliac crest was then palpated in the
midaxillary line. An elastic tape was then applied horizon-
tally midway between the lowest rib margin and the iliac
crest, and tied firmly so that it stayed in position around the
abdomen about the level of the umbilicus.
Biochemical measurements
Subjects were told to avoid strenuous exercise and alcohol
consumption the day before the blood samples were drawn
at baseline and end point. Subjects were fasting when blood
samples were collected. Prostaglandin F2 alpha (PGEF2a)
levels were determined using commercially available ELISA
(enzyme-linked immunosorbent assay) kits (R&D Systems
Inc., Minneapolis, MN, USA) after serum elution in C18
Sep-Pack columns (Isolute SPE column, Argonaut Technolo-
gies, Mid Glamorgan, UK). Glutathione reductase (GSHR)
activity was measured using the test kit from Randox
(Randox Laboratories Ltd., Antrim, UK). Interleukin-6 (IL-6)
concentration in serum was analyzed by ELISA (R&D Systems
Europe Ltd., Abingdon, UK). High-sensitivity C-reactive
protein (CRP) was measured with ELISA.
Statistical analysis
Data were entered into the SPSS statistical package 11.0
(SPSS, Chicago, IL, USA). Data are described as mean±s.d.
The Wilcoxon test was used to calculate whether there were
significant changes in the variables between baseline and
end point. The test was used to calculated differences in
categorical variables between groups. Linear models were
used to calculate the effects of weight loss and diet groups on
end point inflammation parameters; the models additionally
included the variables country, sex and inflammation
parameters at baseline. The variables were log transformed
for these analyses. Results are shown as parameter estimates,
in which three diet groups are compared each with the
control group. The Bs in the parameter estimates were back
transformed and are shown as 1B, thus producing percen-
tage differences between groups with respect to end point
variables. Variances were checked using Levene’s test of
homogeneity, and residuals of the statistical models were
checked for normality using the Kolmogorov–Smirnov test.
Pp0.05 was regarded as statistically significant.
Results
The subjects’ baseline and end point values can be seen in
Table 1. There was significant weight loss in all four groups.
There were significant decreases in all four investigated
inflammation parameters during the 8-week weight loss
program when data were viewed for all subjects together.
Mean changes in all four inflammation parameters were
significant in male subjects; however, only changes in IL-6
and CRP were significant in women. A more detailed
description of gender differences was given in the linear
models (see below).
On a group level, changes were significant for the salmon
and the cod group. The s.d. for most of the inflammation
parameters were huge. PGEF2a decreased in the salmon
group. Significant reductions in IL-6 and CRP were found in
the cod and salmon groups.
Between 43.9 and 73.9% of participants experienced
reductions in inflammation parameters during the 8 weeks,
depending on the inflammation parameter. Correspondingly,
between 56.1 and 26.4% of participants experienced an
increase in inflammation parameters. At average, 52.9, 61.1,
64.2 and 58.4 % of participants experienced reductions in
GSHR, IL-6, CRP and PGEF2a, respectively. Differences
between diet groups were not significant. However, there
was a significant difference between genders with regard to
reduction in GSHR (male¼61.0%, female¼46.8%, P¼ 0.020).
According to the linear models (Table 2), neither diet
groups nor weight loss were significant predictors for end
point GSHR. The male sex was a significant predictor for end
point IL-6 with 14% lower IL-6 concentrations than women.
The linear models for the other three inflammation
parameters indicated only minor (0.7–3%) nonsignificant
differences between genders. Weight loss was the only
significant predictor for end point high-sensitivity CRP.
Surprisingly, the cod group was a predictor for a higher end
point PGEF2a with a 37.2% difference compared with the
control group.
Discussion
In this intervention trial, we investigated the effects of
seafood consumption and weight loss on inflammation
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parameters in overweight and obese European young adults.
The most important finding is that the mean concentrations
of inflammation parameters decrease during a period of
weight loss and seafood consumption. In our study, salmon
consumption was most effective, and three of the four
measured inflammation parameters decreased significantly
in the salmon group.
In vitro studies have shown that LC n-3 PUFAs can affect
inflammation processes both directly (for example, by
replacing arachidonic acid as an eicosanoid substrate and
inhibiting arachidonic acid metabolism) and indirectly (for
example, by altering the expression of inflammatory genes
through effects on transcription factor activation) (Calder,
2006; Margioris, 2009). However, results from human
intervention studies are less convincing and contradicting
(Blok et al., 1997; Jellema et al., 2004; Fujioka et al., 2006; Plat
et al., 2007; Damsgaard et al., 2008). It has been speculated
that potential beneficial effects are difficult to document
because of either the lack of sensitive inflammation markers
or that the beneficial effect of n-3 PUFAs occurs within
tissues, and because of this, it is difficult to detect using
markers of inflammation in the systemic circulation in
which the changes of their concentration is diluted in the
large volume of extracellular fluid (Calder, 2006).
Although the mean concentrations of inflammation
parameters decreased during our intervention, individual
responses to the 8-week program were quite variable.
Between 43.9 and 73.9% (depending on the inflammation
parameter measured) of participants experienced reductions
in inflammation parameters during the 8 weeks. Obviously,
other factors can override the effects of weight loss or
seafood.
It has been reported that the risk of ischemic heart disease
increases by 60% in individuals who have CRP levels above
Table 2 Linear models for the prediction of end point inflammation
parameters
Parameter B 95% CI P-value % Diff.
Dependent variable: end point GSHR (Units/l)
Coda 0.004 0.019 0.011 0.597 0.9
Salmona 0.005 0.020 0.009 0.472 1.2
Fish oila 0.008 0.023 0.007 0.296 1.8
Maleb 0.005 0.016 0.007 0.437 1.0
Weight loss (kg)c 0.000 0.002 0.002 0.949 0.0
Dependent variable: end point IL-6 (pg/ml)
Coda 0.039 0.113 0.035 0.297 8.6
Salmona 0.050 0.123 0.023 0.175 11.0
Fish oila 0.006 0.069 0.081 0.871 1.4
Maleb 0.068 0.124 0.012 0.018 14.4
Weight loss (kg)c 0.007 0.002 0.017 0.131 1.7
Dependent variable: end point hsCRP (mg/l)
Coda 0.055 0.178 0.069 0.385 11.8
Salmona 0.018 0.141 0.105 0.772 4.1
Fish oila 0.037 0.087 0.162 0.557 8.9
Maleb 0.013 0.082 0.108 0.791 3.0
Weight loss (kg)c 0.025 0.041 0.009 0.003 5.6
Dependent variable: end point PGEF2a (pg/ml)
Coda 0.151 0.029 0.273 0.015 41.7
Salmona 0.037 0.157 0.083 0.548 8.1
Fish oila 0.004 0.126 0.119 0.954 0.8
Maleb 0.003 0.089 0.095 0.951 0.7
Weight loss (kg)c 0.000 0.016 0.015 0.956 0.1
Abbreviations: CI, confidence interval; Diff., difference; GSHR, glutathione
reductase; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6;
PGEF2a, prostaglandin F2a.
The statistical models additionally contains inflammation parameter at
baseline and country.
aEstimated differences in end point inflammation parameters relative to the
control group.
bEstimated differences in end point inflammation parameters relative to female.
cEstimated effects of weight loss on inflammation parameters.
The bold values emphasize the significant differences.
Table 1 Baseline and end point data of the participants
Control Cod Salmon Fish oil
Male
(n¼32)
Female
(n¼48)
Male
(n¼35)
Female
(n¼45)
Male
(n¼42)
Female
(n¼42)
Male
(n¼29)
Female
(n¼51)
Mean±s.d. Mean±s.d. Mean±s.d. Mean±s.d. Mean±s.d. Mean±s.d. Mean±s.d. Mean±s.d.
Age (years) 32.6±4.9 31.7±5.6 32.5±5.1 30.4±5.9 31.6±5.6 30.9±5.0 31.0±5.9 30.9±5.0
BMI (basel.) 30.1±1.5 29.9±1.5 30.2±1.2 30.2±1.6 30.5±1.3 30.3±1.5 29.5±1.2 30.1±1.7
Weight (basel.) (kg) 96.7±7.2 81.7±6.7 96.3±7.4 84.2±7.3 97.5±10.6 83.3±6.9 93.0±7.8 80.5±7.0
Weight loss (kg) 5.3*±3.0 3.9*±2.6 6.5*±2.8 4.4*±2.3 7.0*±3.5 3.9*±2.3 6.7*±3.6 4.4*±2.6
GSHR (basel.) (Units/l)** 57.4±5.7 55.0±11.3 59.7±7.4 55.2±6.3 57.0±8.7 54.3±6.3 60.4±8.6 53.6±8.1
GSHR (endp.) (Units/l) 57.3±5.2 54.4±7.2 56.7±8.7 55.6±6.7 54.4±9.5 55.2±6.8 58.3±5.7 52.4±7.4
PGEF2a (basel.) (pg/ml)** 217±203 178±257 223±173 234±266 188±182 202±199 270±451 228±321
PGEF2a (endp.) (pg/ml) 108±87 131±106 251±224 204±204 170±197 148±184 189±141 139±199
IL-6 (basel.) (pg/ml)** 1.32±1.02 1.70±1.59 1.59±1.38 1.73±1.25 1.45±1.12 1.62±1.07 1.94±1.41 2.16±3.81
IL-6 (endp.) (pg/ml) 1.17±0.78 1.68±1.30 1.28±0.87 1.65±2.34 1.14±0.74 1.35±0.69 1.75±1.25 2.09±3.52
CRP (basel.) (mg/l)** 1.77±2.95 3.54±4.39 2.15±2.23 2.81±2.73 2.41±3.02 2.73±2.99 3.66±5.12 3.26±4.60
CRP (endp.) (mg/l) 1.45±1.22 2.44±3.05 1.32±1.40 2.49±4.71 1.54±1.68 1.98±1.96 2.17±2.36 2.70±2.90
Abbreviations: basel., baseline; BMI, body mass index; CRP, C-reactive protein; endp., end point; GSHR, glutathione reductase; IL-6, interleukin-6; PGEF2a,
prostaglandin F2a.
*Significant before–after differences according to Wilcoxon’s signed-ranks test (Po0.05).
**Significant before–after differences according to Wilcoxon’s signed-ranks test (Po0.05) when the data were viewed for all subjects together.
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3mg/l, as compared with those who have CRP levels below
1mg/l (Zacho et al., 2008). In our study population, 27.2%
had high-sensitivity CRP levels above 3mg/l; significant
reductions during the 8 weeks were observed in the cod and
in the salmon group. According to the linear model, weight
loss was a significant predictor with a mean weight loss of
5.16 kg resulting in a 28.4% reduction in high-sensitivity
CRP (keeping all other predictor variables unchanged).
The IL-6 values in our participants were similar to those
reported elsewhere (Cava et al., 2000; Elvevoll et al., 2008).
Reductions after 8 weeks were significant in the cod and
salmon groups, but not in the fish oil or control group.
Reductions of similar size have been previously found in a
Norwegian study providing 1.1 g EPAþDHA per day (Cava
et al., 2000). A smaller study in 30 patients with type II
diabetes mellitus providing a lower daily dose of 0.84 g
EPAþDHA for 12 weeks did not detect significant changes in
IL-6 levels (De Luis et al., 2009). Interestingly, baseline data
categorized by gender and the statistical model indicated
lower IL-6 values for male in comparison with female
participants. The linear models for the other three inflam-
mation parameters indicated only minor (0.7–3%) nonsigni-
ficant differences between genders.
Reduced production of PGEF2a from cell cultures supple-
mented with n-3 PUFAs has been reported (Arntzen et al.,
1998). However, the KANWU study, a recent multicenter
dietary intervention trial, with a controlled fat quality in the
background diet and random assignment to supplementa-
tion with fish oil (3.6 g n-3 PUFA per day) or placebo, did not
detect changes in PGEF2a concentrations (Na¨lse´n et al.,
2006). In our study, significant reductions were observed
only in the salmon group. Mean reductions in the fish oil
and control groups were of similar size; however, the s.d. in
these groups were much larger and thus changes did not
reach statistical significance. According to the linear model,
the cod group had end point PGEF2a concentrations
(corrected for baseline) than did the other three groups
(37.4–59.2% difference), which was also indicated by the
descriptive data. The high LC n-3 PUFA content in the
salmon and fish oil groups can explain the observed
difference. However, the control group ingested even less
LC n-3 PUFA than did the cod group. A possible explanation
for the high PGEF2a concentration in the cod group is that at
end point, the highest content of arachidonic acid in
erythrocyte phospholipids was measured in the cod group,
and the lowest content was measured in the salmon group
(data not shown). Arachidonic acid is the substrate in
cyclooxygenase-mediated PGEF2a formation. As inflamma-
tory cells typically contain a high proportion of n-6 PUFA
arachidonic acid and low proportions of other 20-carbon
PUFAs, arachidonic acid is usually the major substrate for
eicosanoid synthesis. Increased consumption of EPA and
DHA results in increased proportions of those fatty acids in
inflammatory cell phospholipids. The incorporation of EPA
and DHA into human inflammatory cells occurs in a dose–
response manner and is partly at the expense of arachidonic
acid (Calder, 2006). It has been shown that supplementation
of the diet of healthy young men with 1.5 g arachidonic acid
per day for 7 weeks resulted in a marked increase in the
production of several prostaglandins and leukotriens (PGE2,
LTB4) by endotoxin-stimulated mononuclear cells (Kelley
et al., 1998).
In a model of human fibroblast cell culture, n-3 LC PUFA
supplementations results in an elevated catalytic activity of
GSHR, a response which is also confirmed by the induction
of expression of mRNA for GSHR (Arab et al., 2006). In our
study, changes in GSHR were negligible. According to the
linear model, neither diet groups nor weight loss were
significant predictors of end point GSHR activity.
Against our expectations, fish oil consumption did not
significantly decrease any of the four inflammation para-
meters measured. Several reasons might be responsible;
therefore: (1) the daily LC n-3 PUFA dose provided by fish
oil capsules was only half of the amount provided by salmon;
and (2) the variance between subjects in the fish oil group
was large resulting in huge s.d. (see Table 1), which made it
difficult to detect differences as significant. Interestingly, cod
consumption resulted in a significant decrease in two
inflammation parameters, although providing only 0.27 g
LC n-3 PUFA per day. Possibly, other compounds in cod, for
example, sulfur containing amino acids (Elvevoll et al.,
2008), can affect these outcomes.
A limitation of each dietary intervention trial is the
uncertainty of whether the subjects’ dietary intake during
the study period was as reported or prescribed. As there was
intense support of the study participants by our staff,
including frequent phone contact and personal visits, this
risk was minimized.
The interpretation of our results is limited by the fact that
despite the considerable sample size of the SEAFOODplus
YOUNG study, it is likely that the study was underpowered
to detect more significant differences in inflammation
parameters. The observed s.d. of inflammation parameters
were large. The sample size was based on weight loss, the
primary end point of the SEAFOODplus YOUNG study
(Thorsdottir et al., 2007). On the basis of the aimed
recruitment of 320 subjects at baseline, it was estimated
that a 70–80% participation allowed a detection of B1 kg
difference in weight loss between the four diet groups,
assuming a s.d. of 3 kg, a significance P-value of 0.05 and a
statistical power of 0.8. In addition, factors other than of
dietary origin, factors which are beyond control, can affect
inflammation parameters investigated in this study (Borish,
2003).
Conclusions
The mean concentrations of inflammation parameters
decreased during a period of weight loss and dietary
intervention. The individual responses to the 8-week
program were variable, and obviously other factors can
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override the effects of weight loss and seafood. In our study,
salmon consumption was most effective, with three of the
four measured inflammation parameters decreased signifi-
cantly in the salmon group. These findings can be explained
by the high dose of LC n-3 PUFA provided by the salmon diet
in our study.
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